Anticoagulation Forum/LinkedIn
Sep 13, 2025, 13:36
Emerging Evidence on Long-Term Oral Anticoagulation After Provoked VTE: Insights from the HI-PRO Trial
Anticoagulation Forum shared on LinkedIn.
“Join us for our free October webinar: Emerging Evidence: Long-term oral anticoagulation following provoked VTE? A focus on the HI-PRO Trial
Tuesday, October 7, 2025 | 12:00 PM ET
Join us as expert faculty review findings from the recent HI-PRO Trial on the use of apixaban for extended treatment of provoked venous thromboembolism (VTE).
What you’ll learn:
- Key insights from trial design and results
- Clinical implications for real-world practice
- Patient selection considerations for extended therapy
- Faculty:
Arthur Allen, PharmD, CACP – SALT LAKE CITY VA HEALTH CARE SYSTEM
Margaret Fang, MD, MPH – University of California, San Francisco
Gregory Piazza, MD, MS – Brigham and Women’s Hospital”

Register today here.
Read more on Hemostasis Today.
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy
-
Jun 26, 2026, 15:51Heghine Khachatryan: Willebrand Disease – Similar Bleeding Phenotype, Distinct Pathophysiology
-
Jun 26, 2026, 15:37Von Willebrand Disease: New Diagnostic Approaches
-
Jun 26, 2026, 13:58Peter Bou Dib: How Factor IX Transformed Hemophilia B Treatment
-
Jun 26, 2026, 13:49Raghavendra Rao: The Surprising Link Between Chronic Venous Insufficiency and Falls
-
Jun 26, 2026, 13:40Caylynn Carls: Why Genetic Counseling Matters in Hemophilia Treatment